N06AB10 escitalopram
NERVOUS SYSTEM ›PSYCHOANALEPTICS ›ANTIDEPRESSANTS ›Selective serotonin reuptake inhibitors
健保收載品項 TFDA 在效許可證 24 FDA 已核准 健保給付條款 1
台灣藥品與外觀
健保收載品名:"優生"緩優樂膜衣錠10毫克、"晟德"易復樂內服液劑、"隆柏" 立普能膜衣錠10毫克、"隆柏" 立普能膜衣錠5毫克、"隆柏"立普能膜衣錠 15 毫克、"隆柏"立普能膜衣錠 20毫克、"鼎泰"易適普膜衣錠20毫克、依普朗膜衣錠10毫克、安保立喜錠20毫克、得緒安膜衣錠 10 毫克、得緒安膜衣錠 5 毫克、抑克鬱膜衣錠10毫克、抑克鬱膜衣錠20毫克、抑鬱膜衣錠 20 毫克、抑鬱錠10毫克、易坦樂膜衣錠10毫克
無外觀照
草酸右旋西猷普蘭
無外觀照
草酸艾司息達普林
無外觀照
艾司息達普林草酸鹽
資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 鬱症之治療及預防復發、恐慌症、社交焦慮症、泛焦慮症、及強迫症之治療。
- 鬱症之治療及預防復發、恐慌症、社交焦慮症、泛焦慮症及強迫症之治療。
- 憂鬱症之治療及預防復發。
- 精神安定劑(抗憂鬱劑)。
美國 FDA 適應症(英文原文對照)
1 INDICATIONS AND USAGE Escitalopram oxalate is a selective serotonin reuptake inhibitor (SSRI) indicated for: Acute and Maintenance Treatment of Major Depressive Disorder (MDD) in adults and adolescents aged 12 to 17 years ( 1.1 ) Acute Treatment of Generalized Anxiety Disorder (GAD) in adults ( 1.2 ) 1.1 Major Depressive Disorder Escitalopram tablet is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Escitalopram tablet, is indicated for the acute treatment of Generalized Anxiety Disorder (GAD) in adults [ see Clinical Studies ( 14.2 ) ]. Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance.
資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。
健保給付規定
上層 ATC 繼承條款
繼承自 ATC N06AB
§ 1.2.1 戒菸治療藥品 — narrative parent
神經系統藥物 › 精神治療劑
選擇性血清促進素再吸收抑制劑(SSRI)、血清促進素及正腎上腺素再吸收抑制劑(SNRI)及其他抗憂鬱劑(fluvoxamine maleate、fluoxetine、paroxetine、sertraline、venlafaxine、milnacipran、mirtazapine、citalopram、escitalopram、duloxetine、agomelatine、vortioxetine等製劑):(88/12/1、89/10/1、91/5/1、92/6/1、93/5/1、94/2/1、94/12/1、99/10/1、101/7/1、107/3/1) 使用時病歷上應詳細註明診斷依據及使用理由。
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。